Agendia Communicates Strong Data Supporting Breast Cancer Treatment at ASCO 2022

On May 3, 2022 Agendia, Inc., a commercial-stage company focused on empowering decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, reported the presentation of new data from ongoing clinical studies evaluating its comprehensive suite of genomic tests at the upcoming annual conference of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), to be held June 3-7, 2022 in Chicago, Illinois (Press release, Agendia, MAY 3, 2022, View Source [SID1234613435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data underscores Agendia’s clinical commitment to full transcriptome analysis and treatment of breast cancer for underserved populations, in addition to numerous sub-studies stemming from the company’s FLEX Registry, the study in the real world, multicenter, prospective and observational on breast cancer. Two abstracts selected by ASCO (Free ASCO Whitepaper) for oral discussion will present an analysis of the ImPrint genomic test, which is currently indicated for research use only, the I-SPY series of assays, and an analysis of FLEX for receptor breast cancer. positive hormones in black women classified by BluePrint .

The company believes that the FLEX Registry’s approach to cancer research is accelerating the generation of relevant data, aimed at redefining cancer treatment. Its patient-centered design and nationwide network of participating sites leverage Agendia’s infrastructure, enabling investigator-initiated sub-studies to produce notable results with the potential to advance science, such as this. is the case of the data presented at ASCO (Free ASCO Whitepaper) 2022.

Below is information related to the nine Agendia abstracts that have been accepted for discussion or poster sessions at the 2022 ASCO (Free ASCO Whitepaper) Annual Conference:

Poster Discussion Sessions

ImPrint immune signature to identify patients at high risk for breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2
Authors: Kuilman, MM., et al.
Presenter: Lorenza Mittempergher, PhD | R&D, Agendia NV
Session: Breast cancer – local/regional/adjuvant
Poster discussion: Monday, June 6, 2022 | 1: 15-2:45 p.m. CDT
Abstract No.: 514
Full transcriptomic analysis of hormone receptor positive breast cancer in black women classified as basal type by BluePrint
Authors: Reid, S., et al.
Presenter: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center
Session: Breast Cancer – Local/Regional/Adjuvant
Poster Discussion: Monday, June 6, 2022 | 1: 15-2:45 p.m. CDT
Abstract No.: 517
Sessions per poster

Whole transcriptome analysis of tumors with a discordant oncotype and MammaPrint results in the FLEX trial
Authors: Socoteanu, M., et al.
Session: Breast cancer – local/regional/adjuvant
Session date and time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No.: 556
Clinical Implications for Patients with Discordant Oncotype and MammaPrint Results
Authors: Socoteanu, M., et al.
Session: Breast cancer – local/regional/adjuvant
Session date and time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No.: 560
Investigation of a genomic signature for gene amplification of the transcription factor MAF and insufficient benefits of bisphosphonate for early breast cancer
Authors: Nasrazadani, A., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Session Date and Time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No: 559
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy
Authors: Chung, A., et al.
Session: Breast cancer – local/regional/adjuvant
Session date and time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No.: 585
Distribution of Breast Cancer Molecular Subtypes Based on Receptor Classifications: Lessons from the I-SPY2 Trial and the FLEX Registry
Authors: Cha, J., et al.
Session: Breast cancer – local/regional/adjuvant
Session date and time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No.: 592
FLEX, the transcriptomic project for 30,000 breast cancers: a platform for early stage breast cancer research using comprehensive genomic testing coupled with clinical data
Authors: Ma, C., et al.
Session: to be confirmed Session
date and time: Monday, June 6, 2022 | 8h00-11h00 CDT
Abstract No.: TPS612
Defining transcriptomic profiles of early-stage mucinous breast cancers: a FLEX
substudy Authors: Sivapiragasam, A., et al.
Session: Developmental Therapeutics – Molecular Targeting Agents and Tumor Biology
Session Date and Time: Sunday, June 5, 2022 | 8h00-11h00 CDT
Abstract No: 3134
Agendia will be sharing important updates on its Twitter , Facebook and LinkedIn pages throughout the conference. The program for the event is available on the ASCO (Free ASCO Whitepaper) 2022 website .